Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Alendronate + cholecalciferol** is a once-weekly fixed-dose oral combination of alendronate, a nitrogen-containing bisphosphonate, and cholecalciferol, also known as vitamin D3. Alendronate inhibits osteoclast-mediated bone resorption, while cholecalciferol is converted to active vitamin D metabolites that support intestinal calcium absorption and bone mineral homeostasis. Marketed formulations contain 70 mg alendronate with either 2,800 IU or 5,600 IU cholecalciferol. It is approved for osteoporosis in postmenopausal women and to increase bone mass in men with osteoporosis; it is not intended to treat vitamin D deficiency by itself. ([dailymed.nlm.nih.gov](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1))
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alendronate + cholecalciferol.